TENX Earnings — Tenax Therapeutics, Inc. Post-ER Performance | BigEarnings
TENX — Tenax Therapeutics, Inc.
XNAS
Price$11.87
Market Cap$314.9M
P/E—
52W Range$5.34 – $18.38
Next Earnings2026-08-12
About Tenax Therapeutics, Inc.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.
